News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Altor BioScience Corporation Awarded SBIR Phase 2 Grant By NCI For Clinical Development Of Its Novel IL-15 Super Agonist For Non-Muscle Invasive Bladder Cancer


8/19/2014 8:48:48 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MIRAMAR, Fla.--(BUSINESS WIRE)--Altor BioScience Corporation (Altor), a leading developer of cancer immunotherapies, announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase II grant by the National Cancer Institute (NCI) for the clinical development of ALT-803, a proprietary interleukin-15 (IL-15) superagonist protein complex, against non-muscle invasive bladder cancer (NMIBC). NCI ranks bladder cancer as the 6th most common cancer in the U.S., and approximately 70 percent of patients with bladder cancer have NMIBC at diagnosis, making it one of the most prevalent cancers in the U.S.

ALT-803 is considered one of the most promising cancer immunotherapeutic agents by NCI, displaying robust anti-tumor responses in various preclinical cancer models. In preclinical studies, ALT-803 stands out as a potent immunostimulant capable of simultaneously activating the innate and adaptive arms of the immune system to elicit both rapid and long-lasting protective responses against hematologic malignancies and solid tumors, including bladder cancer.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES